Pieper Steven 4

4 · Xeris Biopharma Holdings, Inc. · Filed Mar 5, 2026

Form 4

Period: 2026-03-05

See Remarks

Transactions

Exercise/Conversion
Common Stock
2026-03-05$4.09/sh+27,891$114,074→ 1,394,904 total
Exercise/Conversion
Common Stock
2026-03-05$5.93/sh+14,036$83,233→ 1,408,940 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1]
2026-03-05−27,891→ 0 total
Exercise: $4.09Exp: 2030-12-10→ Common Stock (27,891 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F2]
2026-03-05−14,036→ 0 total
Exercise: $5.93Exp: 2028-01-31→ Common Stock (14,036 underlying)

Footnotes (2)

[F1]The reporting person received the stock options on December 10, 2020 pursuant to an award under the Company's 2018 Stock Option/Stock Issuance Plan. 50% of the options vested on the first anniversary of the vesting commencement date, and the remaining 50% of options vested on the second anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date.
[F2]The reporting person received the stock options on January 31, 2018 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.

Signature

/s/ Beth Hecht, Attorney-in-Fact|2026-03-05

Documents

1 file